欢迎您注册蒲公英
您需要 登录 才可以下载或查看，没有帐号？立即注册
x
FDA Form 483 Frequently Asked Questions FDA 关于483 表的常见问题 Q: When is an FDA Form 483 issued? 问题：什么时候，FDA 签发483 表？ A: An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. FDA investigators are trained to ensure that each observation noted on the FDA Form 483 is clear, specific and significant. Observations are made when in the investigator’s judgement, conditions or practices observed would indicate that any food, drug, device or cosmetic has been adulterated or is being prepared, packed, or held under conditions whereby it may become adulterated or rendered injurious to health. 答案：FDA 检查人员发现某些问题时，根据他们的判断，这些问题可能违反了 FDCA 和相关法案，在检查结束时，签发一份FDA483 表给公司管理层。FDA 检查 人员被培训要求确保FDA483 表上提到的每个问题是清楚的、具体的和具有显著 意义的。根据检查人员的判断，问题、情况和行为将暗示任何食品、药品、医 疗器械和化妆品被掺假，或者在某些情况下北制备、包装和保存，而导致产品 被掺假或者对健康导致伤害。 Q: What is the purpose of an FDA Form 483? 问题：签发483 表的目的是什么？ A: The FDA Form 483 notifies the company’s management of objectionable conditions. At the conclusion of an inspection, the FDA Form 483 is presented and discussed with the company’s senior management. Companies are encouraged to respond to the FDA Form 483 in writing with their corrective action plan and then implement that corrective action plan expeditiously. 答案：FDA483 表的目的是通知公司管理层关于不良情况。在检查结束时，FDA483 表被提出来并和公司高层管理层进行讨论。被检查公司被鼓励以书面形式回复 FDA483 表，包括他们的纠正行动计划和随后对纠正行动的快速实施情况。 Q: Is the FDA Form 483 intended to be an all-inclusive list of every possible deviation from law and regulation? FDA483 表是否是一个针对法律和法规的每个可能偏差的包含一切的目录？ A: No, it’s not. The FDA Form 483 is a report which does not include observations of questionable or unknown significance at the time of the inspection. There may be other objectionable conditions that exist at the firm that are not cited on the FDA Form 483. FDA investigators are instructed to note only what they saw during the course of the inspection. Companies are responsible to take corrective action to address the cited objectionable conditions and any related non-cited objectionable conditions that might exist. 答案：不是，不是这样的。FDA483 表是一份报告，它不包括检查时发现的存疑 的问题或者具有未知意义的问题。有可能被检查公司存在有其他不良情况没有 包含在FDA483 表中。FDA 检查人员被培训为只是引用他们检查过程中看到的问 题。 被检查公司有责任来采取纠正行动来处理被提到的问题，和任何没有被提到的 可能存在的不良情况。 Q: How is the FDA Form 483 shared with the company? FDA483 表是如何和被检查公司分享的？ A: FDA Form 483s are discussed with a company’s management at the conclusion of the inspection. Each observation is read and discussed so that there is a full understanding of what the observations are and what they mean. 答案：在检查最后会议时，FDA483 表被拿来和公司管理层进行讨论。介绍每个 发现的问题并讨论，以便有充分的理解，这些问题是什么？这些问题意味着什 么？ Q: What are the implications of the FDA Form 483 for agency enforcement and what happens next? FDA483 表对FDA 强制行动有什么暗示作用？随后会发生什么？ A: The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations. The FDA Form 483 is considered, along with a written report called an Establishment Inspection Report, all evidence or documentation collected on-site, and any responses made by the company. The Agency considers all of this information and then determines what further action, if any, is appropriate to protect public health. 答案：FDA483 表不构成FDA 最后的决定，关于那些情况是否违反了FDCA 或者违 反了FDCA 的任何相关法规。FDA483 表被一起考虑，连同称为EIR 的书面报告， 现场收集的所有证据和文件，和任何被检查公司做出的反应。FDA 考虑全部这些 信息，然后确定进一步行动，如果可能的话，对于保护公众健康是合适的。 | 
|手机版|蒲公英|ouryao|蒲公英
( 京ICP备14042168号-1 ) 增值电信业务经营许可证编号：京B2-20243455 互联网药品信息服务资格证书编号：(京)-非经营性-2024-0033
发表于 2015-2-4 14:45:51
置顶卡
变色卡
